Splittera split inteins allow to site-specifically modify antibodies with toxins (Antibody drug conjugates, ADCs), fluorescent probes, DNA, peptides and proteins, rendering homogeneous products in a very efficient and cost-effective process.
Splittera for site-specific antibody modification:
- covalently incorporates payloads to the C-terminus of the heavy and light chains of an antibody, yielding DAR 2 or DAR 4 (DAR, drug to antibody ratio)
- the affinity of the antibody for the antigen is not affected
- allows to modify the antibody with two different molecules by using two orthogonal ZIP's inteins, achieving DAR 2+2 in a single reaction
- it can be applied to any antibody format, including bispecific antibodies, Fabs, svFc and others
Learn more in our Site-specific antibody conjugation flyer